Wealth Enhancement Advisory Services LLC Sells 17,117 Shares of Novo Nordisk A/S $NVO

Wealth Enhancement Advisory Services LLC trimmed its holdings in Novo Nordisk A/S (NYSE:NVO) by 8.4% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 186,866 shares of the company’s stock after selling 17,117 shares during the quarter. Wealth Enhancement Advisory Services LLC’s holdings in Novo Nordisk A/S were worth $11,029,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also bought and sold shares of NVO. True Wealth Design LLC boosted its holdings in Novo Nordisk A/S by 209.8% in the 3rd quarter. True Wealth Design LLC now owns 443 shares of the company’s stock valued at $25,000 after purchasing an additional 300 shares during the period. NewSquare Capital LLC raised its position in shares of Novo Nordisk A/S by 174.1% during the second quarter. NewSquare Capital LLC now owns 444 shares of the company’s stock valued at $31,000 after buying an additional 282 shares during the last quarter. Mid American Wealth Advisory Group Inc. bought a new stake in shares of Novo Nordisk A/S in the second quarter valued at about $37,000. Steigerwald Gordon & Koch Inc. acquired a new stake in Novo Nordisk A/S during the third quarter worth about $39,000. Finally, Copeland Capital Management LLC increased its stake in Novo Nordisk A/S by 47.3% during the second quarter. Copeland Capital Management LLC now owns 579 shares of the company’s stock valued at $40,000 after acquiring an additional 186 shares during the period. Institutional investors own 11.54% of the company’s stock.

Analysts Set New Price Targets

NVO has been the topic of several recent research reports. Zacks Research raised Novo Nordisk A/S from a “strong sell” rating to a “hold” rating in a report on Friday, January 9th. HSBC reissued a “hold” rating and issued a $54.00 price target on shares of Novo Nordisk A/S in a report on Wednesday, December 10th. CICC Research started coverage on shares of Novo Nordisk A/S in a research note on Friday, January 9th. They issued an “outperform” rating and a $73.50 price objective for the company. Morgan Stanley reiterated an “underweight” rating and set a $42.00 target price on shares of Novo Nordisk A/S in a research report on Wednesday, December 3rd. Finally, The Goldman Sachs Group reissued a “buy” rating on shares of Novo Nordisk A/S in a research report on Thursday. One equities research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, eleven have given a Hold rating and three have assigned a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of “Hold” and a consensus target price of $56.21.

Novo Nordisk A/S Stock Down 0.0%

NVO opened at $62.22 on Friday. The firm has a market cap of $277.80 billion, a price-to-earnings ratio of 18.09 and a beta of 0.66. The company has a debt-to-equity ratio of 0.52, a quick ratio of 0.57 and a current ratio of 0.78. The firm’s 50-day simple moving average is $52.13 and its 200-day simple moving average is $54.80. Novo Nordisk A/S has a twelve month low of $43.08 and a twelve month high of $93.80.

Novo Nordisk A/S (NYSE:NVO) last released its quarterly earnings results on Wednesday, November 5th. The company reported $1.02 EPS for the quarter, beating analysts’ consensus estimates of $0.77 by $0.25. The firm had revenue of $11.79 billion for the quarter, compared to analyst estimates of $11.98 billion. Novo Nordisk A/S had a net margin of 32.76% and a return on equity of 73.50%. Equities research analysts anticipate that Novo Nordisk A/S will post 3.84 EPS for the current fiscal year.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.